Faster to the right antibiotic treatment - Resistell in Schweizerische Ärztezeitung

On the International Day of Women and Girls in Science, European Innovation Council invited Danuta Cichocka, Resistell CEO, the female scientist and entrepreneur, to share her story about her passion in life science in an interview.

Die Covid-Pandemie hat alle Bereiche des Lebens erfasst. Auch die Startup- und Gründerszene musste mit der Situation umgehen und unter erschwerten Bedingungen die Projekte weiter führen und antreiben. Gleichzeitig aber hat Corona als Katalysator gewirkt für disruptive Ideen, für Innovation und Unternehmergeist.

The Muttenz-based biotech startup proposes an alternative to culture-based antibiograms, the current gold standard in antibiotic susceptibility testing. The EPFL spin-off offers a diagnostic device, the rapid AST method, which is based on the detection of movement caused by living bacterial cells. The new method reduces the time taken to get a result from days to minutes, shows which specific antibiotic is effective against the bacteria, and significantly improves the chances of patients’ survival.

The World Antimicrobial Awareness Week (WAAW) starts today, and this year’s slogan highlights the importance of encouraging best practices when it comes to using antimicrobials. Our portfolio company Resistell is helping to reduce the spreading of antibiotic resistance with their rapid Antimicrobial Susceptibility Testing.

Resistell, the start-up developing world’s fastest phenotypic antibiotic susceptibility test (rapid AST) won the Special Life Science Award in Swiss Innovation Challenge. The prestigious award is a great honour for Resistell and a huge confirmation for the whole team and the product itself.

This year we’ve made a spectacular leap and **ranked 8th**, joining the league of TOP10 most promising start-ups in Switzerland in 2020.

Nanomechanical Sensors as a Tool for Bacteria Detection and Antibiotic Susceptibility Testing

Resistell AG, the start-up developing world’s fastest phenotypic antibiotic susceptibility test was selected for funding under the European Innovation Council (EIC) programme in the latest funding round. Resistell’s project RAPID-SEP-AST will receive up to €2.5M grant and additional equity financing from EIC Fund.

We invite you to study the "Current and near-future technologies for antibiotic susceptibility testing and resistant bacteria detection" published in TrAC Trends in Analytical Chemistry, Volume 127, June 2020 by Jiri Dietvorst, Luïsa Vilaplana, Naroa Uria, Maria-Pilar Marco, Xavier Muñoz-Berbel.

Resistell, EPFL spinoff, located on the brand new 5th floor in Muttenz, is developing world’s fastest antibiotic susceptibility test to help the physicians around the world save patients lives. Our solution is needed more than ever in the context of global pandemics. Last year we have secured CHF 3.5 M in equity financing and won Innosuisse and Eurostars grants. Our core team counts 10 people and we expect to grow further in the next months. Last year we were 34th and among top 5 newcomers on the Top 100 Swiss Startups list. Help us climb faster to the top! Vote now!

Nature Reviews Microbiology: Innovative and rapid antimicrobial susceptibility testing systems

As medical developments zoom ahead, it’s increasingly the startups that are leading the charge. From young teams springing out of Europe’s best medical universities, to entrepreneurs twinning up with expert clinical practitioners who have found a problem to solve, there is no shortage of European medtech startups that are revolutionizing healthcare.

Meet the 5 Swiss startups which took the top spots in the as newcomers in this year's ranking. Each year 100 investors and experts choose their ten favourite young companies with the most promising business idea. The result is the TOP 100 Swiss Startup ranking.